GNFTF - Genfit Announces Positive Data For Chronic Liver Disease Using Its NASH Drug
Recently, Genfit (OTCPK:GNFTF) announced that it had received positive results treating patients with primary biliary cholangitis (PBC). These positive results were obtained using the company's NASH drug elafibranor. Positive results from the study were obtained after patients were treated over a 12-week period. Even though this was a small study, the drug clearly proved to work in this patient population. It believes that it has enough data to move on to the next stage of clinical development.
Phase 2 Data
The phase 2 study recruited patients both in the U.S. and in Europe.